Batavia Biosciences is partnering with an international consortium, coordinated by international non-profit organisation, PATH, to develop and manufacture safer novel oral poliovirus vaccines (nOPV).
Stop polio
This project has the potential to ensure eradication of polio is maintained. The nOPV candidates being developed, intended to reduce risk from rare cases of vaccine-associated disease, will be stockpiled in readiness for protection against possible future outbreaks.
Chris Yallop, CSO of Batavia Biosciences, explained: “With such a consortium, I am convinced that we will succeed in taking the next step in the development of this much needed vaccine.”
Menzo Havenga, CEO of Batavia Biosciences, added: “We are proud to work with the Bill & Melinda Gates Foundation PATH, NIBSC and BioFarma, and on the goal of bringing a safer oral polio vaccine to help keep the world polio-free.”
The novel candidate vaccine strains currently in manufacturing at Batavia Biosciences have been developed by the National Institute for Biological Standards and Control (NIBSC) in the United Kingdom, the U.S. Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), and the University of California at San Francisco (UCSF). Batavia Biosciences contributes its extensive polio vaccine development experience and works closely with one of the world’s leading OPV vaccine manufacturers, BioFarma, in Indonesia, under the nOPV consortium managed by PATH.